Changes in the lymph nodes during the earliest phases of rheumatoid arthritis

Completed

• Conditions: arthritis; Rheumatoid arthritis; 10003816

• Registration Number: NL-OMON38509
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

Healthy controls: negative for IgM-RF and anti-CCP antibodies
Autoantibody-positive individuals: positive for IgM-RF and/or anti-CCP antibodies + either arthralgia or a first degree relative with RA.
Early arthritis patients: arthritis < 1 year, disease-modifying antirheumatic drug (DMARD) naive + classified as RA according to the 2010 ACR/EULAR criteria for RA or as unclassified arthritis (UA).

Exclusion Criteria

For all individuals:
- Current/previous use of disease modifying anti-rheumatic drugs (DMARDs).
- If applicable: patients in whom anticoagulant therapy cannot be temporarily stopped before the procedure
- Systemic prednisolone use less then 28 days before enrolment
- Present or previous treatment with any cell depleting therapies, including investigational agents (e.g. CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19)
- Presence of any disease for which study subjects need chronic or intermittent immunosuppressive therapy (e.g. prednisolone for COPD).
- History of chronic viral infection
- History of autoimmune diseases
- History of malignancies

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified